1、KPMG.Make the Difference.KPMG Life Sciences CEO OutlookKPMG I life sciences sector is made up of a diverse ecosystem of companies and segments.They range from massive global pharma companies and regional lab powerhouses to small startup device manufacturers and innovative biotech research labs.No tw

2、o life sciences companies face the same challenges or opportunities.And there is no typical life sciences CEO.Yet this survey of 120 life sciences CEOs around the world suggests there are common themes and strategies at play.As life sciences organizations across the spectrum focus on driving innovat

3、ion,many are struggling to accelerate digitalization and the adoption of AI.They recognize the importance of environmental,social and governance(ESG)on public trust and growth but arent sure they can meet their net zero objectives.Talent gaps and capability shortages emerge as continuous themes thro

4、ughout.At the same time,our 2024 Life Sciences CEO Outlook suggests sector CEOs are confident about their growth prospects and many believe they have a winning strategy in place to carry their organization into the future.Expect to see significant organic growth,coupled with savvy inorganic maneuver

5、s and big investments into new technologies and portfolios over the next three years.It is worth noting that while a significant number of the worlds largest pharmaceutical companies participated in our survey the vast majority of the respondents represent smaller organizations(more than US$500M but

6、 less than US$10B in annual revenues)biopharmaceuticals,medical device manufacturers,lab and medical testing organizations,distributors and so on.Simply put,the survey respondents reflect the broad ecosystem that is life sciences.In this report,we unpack the key themes revealed by our survey of sect